[{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Suzhou Abogen Biosciences | Walvax Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Walvax Biotechnology \/ Suzhou Abogen Biosciences | Walvax Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Biotechnology \/ Suzhou Abogen Biosciences | Walvax Biotechnology"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"13-Valent Pneumococcal Polysaccharide Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Walvax Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Walvax Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Walvax Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HPV9 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Walvax Biotechnology \/ Walvax Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Biotechnology \/ Walvax Biotechnology"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Sirnaomics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2021","type":"Partnership","leadProduct":"STP702","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Walvax Biotechnology","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"Walvax Biotechnology \/ Sirnaomics","highestDevelopmentStatusID":"5","companyTruncated":"Walvax Biotechnology \/ Sirnaomics"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Walvax Mpv Acyw Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Walvax Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Walvax Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Walvax Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"202-CoV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walvax Biotechnology \/ Walvax Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Walvax Biotechnology \/ Walvax Biotechnology"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Walvax Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ZR-202-CoV","moa":"SARS-CoV-2 S protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walvax Biotechnology \/ Walvax Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Walvax Biotechnology \/ Walvax Biotechnology"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Walvax Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"202-CoV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walvax Biotechnology \/ Walvax Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Walvax Biotechnology \/ Walvax Biotechnology"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"RNAcure Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RQ3013","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walvax Biotechnology \/ RNAcure Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Walvax Biotechnology \/ RNAcure Biopharma"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"RNAcure Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RQ3013","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walvax Biotechnology \/ RNAcure Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Walvax Biotechnology \/ RNAcure Biopharma"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walvax Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Walvax Biotechnology \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Walvax Biotechnology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 07, 2023

                          Lead Product(s) : 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          October 14, 2022

                          Lead Product(s) : HPV9 Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Shanghai Zerun Biotechnology Co.,Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 31, 2022

                          Lead Product(s) : RQ3013

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : RNAcure Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 27, 2022

                          Lead Product(s) : RQ3013

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : RNAcure Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 06, 2022

                          Lead Product(s) : ZR-202-CoV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Shanghai Zerun Biotechnology Co.,Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : ARCoV or ARCoVax, China's first mRNA vaccine to enter Phase III trials, jointly developed by the People's Liberation Army (PLA) Academy of Military Sciences, Suzhou Abogen Biosciences and Walvax Biotechnology Co., Ltd.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 05, 2021

                          Lead Product(s) : SARS-CoV-2 mRNA Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 04, 2021

                          Lead Product(s) : 202-CoV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Shanghai Zerun Biotechnology Co.,Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 29, 2021

                          Lead Product(s) : 202-CoV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : Shanghai Zerun Biotechnology Co.,Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The partnership will specifically focus on development of the siRNA-based anti-influenza therapeutic candidate STP702. Walvax will get an exclusive development and commercialization rights for territories including mainland China, Taiwan, Hong Kong and M...

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          April 29, 2021

                          Lead Product(s) : STP702

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Sirnaomics

                          Deal Size : $6.4 million

                          Deal Type : Partnership

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 15, 2021

                          Lead Product(s) : SARS-CoV-2 mRNA Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Suzhou Abogen Biosciences | Walvax Biotechnology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank